# Bioprocess Market Watch. November 2026 edition for European suppliers

So far, ClinicalTrials.gov counts 4 industry biologics trials started in Europe in October 2026. The count is provisional, because many studies are registered weeks after they start. This edition covers open data up to 31 October 2026, or the latest month published, on trials, medicine approvals, equipment imports into the EU and registrations in Brazil, for anyone running marketing or sales at a European bioprocess supplier.

[Web version](https://www.crida.studio/en/insights/guides/bioprocess-market-watch-2026-11/)

By David Monje, crida studio · Published 2026-11-15 · Updated 2026-11-15

## What the official records say about October 2026

In October 2026, 64 industry biologics trials started worldwide, 24 in the United States, 20 in Asia and 4 in Europe. In the last twelve months, only March had more worldwide, with 74. The EMA authorised 1 medicine and the FDA approved 2. The FDA also issued 14 CGMP warning letters. EU import data run to August 2026.

Europe's 4 is provisional and the lowest figure of the twelve months. Many studies reach ClinicalTrials.gov weeks after they start, so the latest month usually rises. That is what happened to September. In [the October edition](https://www.crida.studio/en/insights/guides/bioprocess-market-watch-2026-10/), with data downloaded on 1 November 2026, September had 10 trials in Europe, and the 15 November download gives it 13.

Indicators for October 2026 compared with September, counts of official records downloaded on 15 November 2026. October figures may still change.

| Indicator | Month | Previous month | Change |
| --- | --- | --- | --- |
| Biologics trials started in Europe | 4 | 13 | -9 |
| Biologics trials started worldwide | 64 | 62 | +2 |
| Biologics trials started in the United States | 24 | 22 | +2 |
| Biologics trials started in Asia | 20 | 18 | +2 |
| Medicines authorised by the EMA | 1 | 7 | -6 |
| FDA approvals, CDER and CBER | 2 | 10 | -8 |
| FDA CGMP warning letters | 14 | 13 | +1 |

## EMA authorisations and FDA approvals from May to October 2026

In October 2026, the EMA authorised 1 human medicine through the centralised procedure, and it was not a biosimilar. The FDA approved 2, both novel drugs from CDER, while CBER approved no new licenses. Over the six months in the chart, the EMA peaks in July with 8, and the FDA in August and September with 10.

A month with 1 or 2 approvals does not signal a change of direction. The EMA authorises in batches, and the series has 14 medicines in November 2025 and only 1 in December. Recent CBER licenses may not be on the FDA page yet. And the EMA table only flags biosimilars, so it does not say whether October's medicine is a biologic.

![Grouped bar chart of EMA authorisations and FDA approvals by month, from 6 and 8 in May to 1 and 2 in October 2026.](https://www.crida.studio/recursos/assets/ema-authorisations-and-fda-approvals-to-october-2026-november-edition.74f4be455026.svg)

EMA authorisations and FDA approvals to October 2026, November edition

| Month | EMA | FDA |
| --- | --- | --- |
| May 2026 | 6 | 8 |
| Jun 2026 | 5 | 4 |
| Jul 2026 | 8 | 8 |
| Aug 2026 | 4 | 10 |
| Sep 2026 | 7 | 10 |
| Oct 2026 | 1 | 2 |

Medicines authorised by the EMA and approved by the FDA, with CDER and CBER combined, each month from May to October 2026.

Source: [EMA medicines table and FDA, CDER and CBER approvals](https://www.ema.europa.eu/en/medicines/download-medicine-data)


### How many biologics trials started in Spain in October 2026?

ClinicalTrials.gov counts 1 industry trial with at least one biological intervention and a site in Spain, against 3 in September. The figure is provisional, from the database as of 13 November 2026, and may rise once studies that have already started are registered. A study with sites in Spain and other countries counts in each country.

## Where industry biologics trials started in October 2026

By territory, the United States had 24 new trials in October 2026, Asia 20, Europe 4 and Latin America 1. The count covers industry-sponsored interventional studies with at least one biological intervention, by the start month recorded on ClinicalTrials.gov. A study with sites in several countries counts in each country and once in each territory.

In the country breakdown, Switzerland has 2, and Germany and Spain 1 each. France, Italy, the United Kingdom, the Netherlands, Belgium and Poland have none yet. The European total also includes countries outside the breakdown, and one study can count in more than one country, so the 4 do not necessarily come from those three.

For a supplier, behind each new trial is a sponsor that needs clinical trial material, often made in its own pilot plant or at a CDMO. The count understates the total, because many [monoclonal antibody trials](https://www.crida.studio/en/insights/guides/monoclonal-antibody-clinical-trials-europe-2026/) are registered as DRUG rather than BIOLOGICAL. For Europe, look at all twelve months, which range from 6 to 17 outside October.

![Bar chart of industry biologics trials started in October 2026, with 24 in the United States, 20 in Asia, 4 in Europe and 1 in Latin America.](https://www.crida.studio/recursos/assets/biologics-trials-started-in-october-2026-by-territory-november-edition.2583ccbbbe05.svg)

Biologics trials started in October 2026 by territory, November edition

| Territory | Trials started |
| --- | --- |
| Europe | 4 |
| United States | 24 |
| Asia | 20 |
| Latin America | 1 |

Interventional industry trials with at least one biological intervention started in October 2026, by territory, from the database as of 13 November 2026. Provisional count.

Source: [ClinicalTrials.gov, API v2](https://clinicaltrials.gov/api/v2/studies)

## Imports under 8419.89 into the 27 EU member states in August 2026

Eurostat publishes with a lag, and August 2026 is the latest month with data for all 27 member states, updated on 13 November. That month, the 27 imported 162,202 thousand euros under subheading 8419.89, against 194,616 in July (-16.7%). Germany imported 41,098 thousand euros, the Netherlands 15,541, France 13,476 and Spain 11,070, fourth on the list.

Subheading 8419.89 covers many machines for treating materials through a change of temperature, and bioreactors and fermenters are only part of it. It counts what enters each state from anywhere, other EU states included, in current euros. Eurostat may still revise August, and one month is not a trend.

![Bar chart of imports under subheading 8419.89 in August 2026, from Germany with 41,098 thousand euros to Italy with 6,980, with Spain fourth at 11,070.](https://www.crida.studio/recursos/assets/imports-under-subheading-8419-89-in-august-2026-november-edition.dda94592972a.svg)

Imports under subheading 8419.89 in August 2026, November edition

| Member state | Thousand euros |
| --- | --- |
| Germany | 41,098 |
| Netherlands | 15,541 |
| France | 13,476 |
| Spain | 11,070 |
| Austria | 9,796 |
| Ireland | 8,485 |
| Hungary | 8,393 |
| Italy | 6,980 |

The eight member states with the highest imports under subheading 8419.89 in August 2026, the latest month with data for all 27, in thousand euros.

Source: [Eurostat, Comext DS-045409](https://ec.europa.eu/eurostat/web/international-trade-in-goods/database)


### Why does Europe show only 4 trials in October 2026?

Because the count is still incomplete. October is the last month in this edition and many studies are registered weeks after they start. September shows how this works, with 10 trials in Europe in the 1 November 2026 download and 13 in the 15 November one. The 4 is the lowest figure of the twelve months, but it does not yet point to a decline.

## What the data show for Asia and Latin America in October 2026

In Asia, 20 biologics trials started in October 2026, and 15 of them have a site in China. South Korea has 3, Japan 2 and India 1. Latin America had 1, with a site in Colombia, while Brazil, Mexico, Argentina and Chile have none yet.

In Brazil, ANVISA registered 7 biological medicines in October and 6 in September, and the highest month in the series is April 2026, with 20. In Japan, the PMDA list has 135 new drug entries for FY2024, from April 2024 to March 2025. FY2025, still partial, has 119 entries up to February 2026.

Asia here means only Japan, China, India and South Korea, and Latin America means Brazil, Mexico, Argentina, Colombia and Chile. Studies that appear only in a national registry are left out. The ANVISA file of 13 November has no registration date, so the process completion date is used. PMDA entries include new indications and doses and serve only as context.


### Do these counts measure demand for bioprocess equipment?

No. The figures are counts of official records, such as a study starting, a medicine being authorised or an FDA letter, plus the value imported under a subheading that covers far more than bioreactors. They show where the sector is moving, but they do not say how much bioprocess equipment is bought, in units or in euros. That is why there are no market sizes or forecasts here.

## What a European bioprocess supplier can do with the October figures

For the coming quarter, these figures do not call for big changes. The United States, with 24 new trials, and Asia, with 20, stay within their range of the past year, so if you already sell there, keep up the effort. In Europe, check each country's twelve months in this edition's CSV file before cutting back, because the 4 is provisional. In Spain, with 1 trial in October and 3 in September, one month says little.

With trial sponsors, talk about clinical trial material, scale-up and GMP documentation. For the United States, make sure your English content answers technical questions so buyers do not need to call. For Asia, decide the language with your distributor in each country. Germany was the largest importer under subheading 8419.89 in August, but the subheading covers far more than bioreactors. If you want to sell there, it helps to have your [key pages in German](https://www.crida.studio/en/insights/guides/market-bioprocess-equipment-germany/).

Make sure your website and datasheets state the scale each system works at and the GMP documentation that comes with it, and share them with your distributors. If you are going to a trade show before the next edition, bring these figures with their download date. crida studio does [marketing for bioprocess equipment makers](https://www.crida.studio/en/insights/services/biotech-bioprocess-pharma-marketing/) and life science companies, and its founder ran marketing at a European manufacturer for three and a half years.

## What changed compared with September 2026

Compared with September, trials rise from 62 to 64 worldwide (+3.2%), from 22 to 24 in the United States (+9.1%) and from 18 to 20 in Asia (+11.1%). Europe goes from 13 to 4, and Latin America and Spain from 3 to 1, with October still incomplete. The September figures come from the 15 November download, and some no longer match those in the October edition.

The EMA goes from 7 authorisations to 1 and the FDA from 10 approvals to 2. CGMP warning letters rise from 13 to 14 (+7.7%), and October may still add more. Imports under subheading 8419.89 fall 16.7% from July to August. In the chart, worldwide trials range from a low of 39 in July to a high of 74 in March, and October, at 64, is the second-highest month.

![Line chart of biologics trials started worldwide each month, from 42 in November 2025 to 64 in October 2026, with a high of 74 in March and a low of 39 in July.](https://www.crida.studio/recursos/assets/biologics-trials-started-worldwide-to-october-2026-november-edition.e413054e8034.svg)

Biologics trials started worldwide to October 2026, November edition

| Month | Trials |
| --- | --- |
| Nov 2025 | 42 |
| Dec 2025 | 62 |
| Jan 2026 | 57 |
| Feb 2026 | 56 |
| Mar 2026 | 74 |
| Apr 2026 | 54 |
| May 2026 | 49 |
| Jun 2026 | 58 |
| Jul 2026 | 39 |
| Aug 2026 | 44 |
| Sep 2026 | 62 |
| Oct 2026 | 64 |

Interventional industry trials with at least one biological intervention started worldwide each month, November 2025 to October 2026. October is still provisional.

Source: [ClinicalTrials.gov, API v2](https://clinicaltrials.gov/api/v2/studies)


### Where can I download the data and how were they counted?

The figures can be downloaded as CSV and JSON from this page, with the source and download date of each value. Scripts read the eight official sources with the same filters every month, without estimates. The method section at the end of the page gives the exact query and the limits of each source.

## Sources, queries and limits of this edition

All sources were downloaded on 15 November 2026. The data run to 31 October 2026, except Eurostat, which runs to August, and the PMDA list, which runs to February 2026. These are counts of official records and, for Eurostat, import values, with no estimates of our own. They do not measure orders or sales of bioprocess equipment. The latest month of each series can still move. Below are the exact query and limits for each source.


- [EMA, medicines table](https://www.ema.europa.eu/en/medicines/download-medicine-data). File medicines-output-medicines_json-report_en.json of the medicines table on the Download medicine data page, with the keys category, marketing_authorisation_date and biosimilar. Rows with category equal to Human and marketing_authorisation_date within the month. Biosimilars are the subset with biosimilar equal to Yes.. Downloaded on 2026-11-15. Centralised procedure medicines only. Counted by marketing authorisation date, including medicines later withdrawn. Includes generics and biosimilars. The table flags biosimilars but does not single out other biologics. The EMA updates the file twice a day and figures may shift slightly.
- [FDA, CDER novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026). Table on the Novel Drug Approvals page for 2025 and 2026, one row per approval, counted by the month in the Approval Date column.. Downloaded on 2026-11-15. New molecular entities and new therapeutic biological products approved by CDER only. Excludes generics, biosimilars and new indications for products already approved.
- [FDA, CBER biologics license approvals](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2026-biological-license-application-approvals). Table on the Biological License Application Approvals page for 2025 and 2026, one row per license, counted by the month in the Approval Date column.. Downloaded on 2026-11-15. New CBER licenses, such as vaccines, blood products and gene therapies, plus some diagnostic reagents and tests licensed as BLAs. Excludes supplements to licenses already approved. Approvals from the last few weeks may not be on the page yet.
- [FDA, warning letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters). Full table on the Warning Letters page, 3,807 letters on the download date, read through the table's own data endpoint with the same columns as the XLSX export. Rows with Issuing Office CDER or CBER and CGMP in Subject, counted by the month of Letter Issue Date.. Downloaded on 2026-11-15. The FDA posts each letter days or weeks after issuing it, so recent months may still rise. Only CDER and CBER letters count, not those from other FDA centers and offices such as foods, medical devices, veterinary medicine or inspections. The subject is set by the FDA and mixes finished drugs, active ingredients and biologics. The page's XLSX export returns at most 1,000 rows, so it was not used.
- [ClinicalTrials.gov, API v2](https://clinicaltrials.gov/api/v2/studies). ClinicalTrials.gov API v2, /api/v2/studies with countTotal=true, pageSize=1 and fields=NCTId, reading totalCount. For each month, filter.advanced equal to AREA[StartDate]RANGE[2026-10-01,2026-10-31] AND AREA[StudyType]INTERVENTIONAL AND AREA[LeadSponsorClass]INDUSTRY AND AREA[InterventionType]BIOLOGICAL AND AREA[LocationCountry]COVERAGE[FullMatch]"Spain", where the last term is replaced by the territory's country or an OR of its countries, and dropped for the world. Europe is the 27 EU member states plus the United Kingdom, Switzerland, Norway and Iceland. Asia is Japan, China, India and South Korea. Latin America is Brazil, Mexico, Argentina, Colombia and Chile.. Downloaded on 2026-11-15. A count of study records, not of equipment demand. Each study falls in the month of its start date, which in some records is still an estimate. A study with sites in several countries counts in each country, so the countries add up to more than the territory total. Many studies are registered weeks after they start, so recent months may rise. The intervention type is chosen by whoever registers the study and many antibodies are registered as DRUG, so the count falls short. Database updated on 13 November 2026.
- [Eurostat, Comext DS-045409](https://ec.europa.eu/eurostat/web/international-trade-in-goods/database). Comext dissemination API, ec.europa.eu/eurostat/api/comext/dissemination/statistics/1.0/data/DS-045409 with freq=M, reporter set to each of the 27 member states, partner=WORLD, product=841989, flow=1 (imports), indicators=VALUE_IN_EUROS and sinceTimePeriod=2024-01. The EU27 total is the sum of the 27 states and is only computed for months with data for all 27.. Downloaded on 2026-11-15. Subheading 8419.89 covers other machinery, plant and laboratory equipment for treating materials through a change of temperature, and includes much equipment that is neither a bioreactor nor a fermenter. These are each state's imports from any country, including other EU states, in current euros. The latest month with data for all 27 states within the edition period is August 2026, and Eurostat may revise the figures. Data updated on 13 November 2026.
- [ANVISA, open medicines data](https://dados.anvisa.gov.br/dados/). File DADOS_ABERTOS_MEDICAMENTOS.csv in the ANVISA open data directory, Latin-1 encoded and semicolon separated. Rows with CATEGORIA_REGULATORIA equal to Biológico, counted once per NUMERO_REGISTRO_PRODUTO, by the month of DATA_FINALIZACAO_PROCESSO.. Downloaded on 2026-11-15. The file has no registration date column, so the process completion date is used. The file repeats rows for the same registration and each registration number is counted once. It includes registrations now inactive and drops dates with impossible years. File updated on 13 November 2026, and the months since then are not given because they are not complete yet.
- [PMDA, list of approved drugs](https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html). PDF «April 2004 to February 2026 [3.06 MB]» linked from the List of Approved Products page, converted to text with pdftotext. One entry per number in each New Drugs Approved section, assigned to a fiscal year by approval date.. Downloaded on 2026-11-15. Counts new approvals and partial changes, such as new indications or doses, not only new active ingredients. One entry may group several presentations. The PDF runs to February 2026 and the current fiscal year is partial. It is context and is not compared month by month.

## Open data

- [observatori-bioproces-2026-11.csv](https://www.crida.studio/recursos/dades/observatori-bioproces-2026-11.csv)
- [observatori-bioproces-2026-11.json](https://www.crida.studio/recursos/dades/observatori-bioproces-2026-11.json)

## References

- [EMA, medicines table](https://www.ema.europa.eu/en/medicines/download-medicine-data)
- [FDA, CDER novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)
- [FDA, CBER biologics license approvals](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2026-biological-license-application-approvals)
- [FDA, warning letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)
- [ClinicalTrials.gov, API v2](https://clinicaltrials.gov/api/v2/studies)
- [Eurostat, Comext DS-045409](https://ec.europa.eu/eurostat/web/international-trade-in-goods/database)
- [ANVISA, open medicines data](https://dados.anvisa.gov.br/dados/)
- [PMDA, list of approved drugs](https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html)

## The crida perspective

We are a marketing, brand and technology studio based in Girona. We bring identity, content and development together so a digital experience makes sense from beginning to end.

crida studio, Caldes de Malavella (Girona, Spain). David Monje, founder and director.

## Want this analysis applied to your target markets?

All the data in this edition are public and downloadable. If you want the same analysis for your product portfolio, get in touch and we will prepare it with you in a thirty-minute session.

[Ask for a session](https://www.crida.studio/en/#contact)

## More on web design

- [Bioprocess Market Watch. October 2026 edition for European suppliers](https://www.crida.studio/en/insights/guides/bioprocess-market-watch-2026-10/)
- [Bioprocess Market Watch. Every edition and its open data](https://www.crida.studio/en/insights/guides/bioprocess-market-watch/)
- [What European bioprocess equipment makers’ websites look like in 2026](https://www.crida.studio/en/insights/guides/european-bioprocess-manufacturer-websites-2026/)
- [Trade show cost calculator for bioprocess equipment makers](https://www.crida.studio/en/insights/guides/trade-show-cost-calculator-bioprocess/)
- [Marketing for biotech, bioprocess and pharma companies](https://www.crida.studio/en/insights/services/biotech-bioprocess-pharma-marketing/)
- [Life science market research with free public data, step by step](https://www.crida.studio/en/insights/guides/life-science-market-research-free-data/)
- [Scandinavia, Germany or Asia, how to pick your next export market](https://www.crida.studio/en/insights/guides/choose-export-market-equipment/)
